Skip to content

Public FDA record

Z-2639-2026: Brand Name: Pilling Wecksorb Product Name: Pilling Wecksorb Neurosponges (Cotton) Pilling Wecksorb Neuros

Recall record Z-2639-2026 for TELEFLEX LLC. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-2639-2026
Company in FDA record
TELEFLEX LLC
FDA classification date
Jul 1, 2026
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

Due to out-of-specification, or potential out-of-specification, levels of endotoxins

Source facts

Action
On 05/07/2026, the firm sent via email and FedEx an "URGENT MEDICAL DEVICE RECALL" Letter informing customers that firm is recalling Pilling Wecksorb Neurosponge lots due to out-of-specification/potential out-of-specification levels of endotoxin. Medical facilities are instructed: 1. Immediately check inventory, cease use and immediately quarantine affected products. 2. For affected product, mark the applicable checkbox on the Acknowledgement Form and contact Customer Service: a. Fax, including Attn: Customer Service , or email customer service. OR b. Using the online FSN Portal, complete the acknowledgement form virtually using the following link: https://fca.myteleflex.com/en/recall/000596 Note: Option b is only available to customers who received product directly from Teleflex. 3. If no affected product, mark the applicable checkbox on the Acknowledgement Form and return the form to Teleflex. 4. A customer service representative will provide a Return Goods Authorization Number and instructions for the return of products. Teleflex/local dealer will issue a credit note upon receipt of the returned affected product. Distributors 1. Provide copy of recall notice to all customers who received impacted product. Each customers is required to complete the Acknowledgement Form and return it to distributor. 2. Immediately check inventory, cease use and distribution, and immediately quarantine. Return all product in scope. 3. Confirm that field activity have been completed. Forward completed Acknowledgement Form to the e-mail address below. Important - Please ensure only listed batch numbers in scope are listed. Acknowledgement form can be submitted virtually: https://fca.myteleflex.com/en/recall/000596 4. If affected products have been distributed outside of your country, notify Teleflex Customer Service by return email to the email address provided below. For questions - Customer Service 1-866-396-2111, FAX: 1-855-419-8507 Email: Recalls@teleflex.com
Initiated
2026-05-07
Root cause
Device Design
Distribution
Worldwide - U.S. Nationwide distribution including in the states of AK, AL, AR, AZ, CA, CO, CT, FL, GA, HI, IA, ID, IL, IN, KS, KY, MA, MD, ME, MI, MN, MO, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WI, and WV. The country of Panama.
Recall number
Z-2639-2026
Recall status
Open, Classified
CDRH record ID
220287
FDA classified
2026-07-01
Recall event number
98962

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗